Immix Biopharma, Inc. (IMMX) intrinsic value & 10-year financials
Immix Biopharma, Inc. (IMMX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $7.98
- Market cap
- $263.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 138.2%
- Free cash flow (FY2025)
- -$24.7M
IMMX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$29.4M | -$0.89 | -$24.7M | — | 2286.8% |
| FY2024 | — | -$21.6M | -$0.76 | -$15.8M | — | 662.8% |
| FY2023 | — | -$15.4M | -$0.89 | -$11.4M | — | -109.2% |
| FY2022 | — | -$8.2M | -$0.59 | — | — | -2077.7% |
| FY2021 | — | -$24.4M | — | -$1.6M | — | 57.8% |
| FY2020 | — | -$1.1M | — | — | — | 8.9% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Immix Biopharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Immix Biopharma, Inc. has earned high returns on invested capital, averaging 15.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Immix Biopharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Immix Biopharma, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.